Santaris Pharma releases positive data on LNA-based survivin inhibitor
Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company’s proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.
The data on SPC3042 was published in the September 2008 issue of the journal Molecular Cancer Therapeutics.
Read the rest of this entry »